Subtype
Low Grade Glioma
CI-CAN-00003062LGGExplore in graph →
Non-malignant115 active trials62 evidence items
- NCIt
- C132067
- OncoTree
- LGGNOS
- DOID
- 0080829
- Other
- 1 more code
Loading cancer entity…
Subtype
CI-CAN-00003062LGGExplore in graph →
Clinical trials
324 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04105374 | Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma | withdrawn | Phase 2 / Phase 3 | 0 | NRG OncologyOTHER | 0 | May 7, 2026 | clinicaltrials |
| NCT05222165 | Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations(NEWEL) | withdrawn | Phase 1 / Phase 2 | 0 | Helsinn Healthcare SAINDUSTRY | 3 |
| Feb 23, 2023 |
| clinicaltrials |
| NCT03649464 | Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants | withdrawn | Phase 1 / Phase 2 | 0 | Oblato, Inc.INDUSTRY | 0 | Oct 7, 2022 | clinicaltrials |
| NCT03014804 | Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT02689336 | Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Sep 9, 2019 | clinicaltrials |
Data updated 22 days agoSource updated May 7, 2026source: clinicaltrials